Activating mutations in the epidermal growth factor receptor (EGFR) are common driver
mutations in non-small cell lung cancer (NSCLC). First, second and third generation EGFR …

Epidermal growth factor receptor (EGFR) targeted therapy is one of the most important and
effective strategies to combat EGFR mutant nonsmall-cell lung cancer (NSCLC). However, a …

Although epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFRi) are
approved for treating EGFR-mutant lung adenocarcinoma (LUAD), emergence of acquired …

Epidermal growth factor receptor (EGFR) is essential for normal cellular functions. Mutations
of EGFR's kinase domain can cause dysregulation leading to non-small cell lung cancer …

Most EGFR exon 20 insertion (EGFR ex20ins) driver mutations in non–small cell lung
cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To …

Non-small cell lung cancer (NSCLC) is a deadly and highly prevalent malignancy. Targeting
activated-EGFR mutations in NSCLC via EGFR tyrosine kinase inhibitor (EGFR-TKI) initially …

In the treatment of non–small cell lung cancer (NSCLC), patients harboring exon 20
insertion mutations in the epidermal growth factor receptor (EGFR) gene (EGFR) have few …

Epidermal growth factor receptor (EGFR) mutations are the molecular driver of a subset of
non-small cell lung cancers (NSCLC); tumors that harbor these mutations are often …

Protein-protein interaction networks (PPIs) govern the majority of biological processes, but
how oncogenic mutations impact these interactions and their functions at a network scale is …

Epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors (TKIs) have
emerged as first-line drugs for non-small cell lung cancers (NSCLCs). However, the …